An excerpt from the end of the article:
Marc Voigt: Yeah, 2023 will be very exciting, but also 2022 is not over, so we expect a number of different news, and 2023, we’ll see more data, very important data and may highlight TACTI-003, a trial in first-line head and neck cancer. Potential readout is some time mid of next year. So, by our standards in the relative near-term. We will have additional data from TACTI-002, INSIGHT-003, we will provide regulatory updates, we will see the expansion of the pipeline. We will have hopefully also news from the variety of the different partners we are having in China. I mentioned Novartis, I mentioned Glaxo and others. So, there’s a lot to expect. And despite the difficult year, 2022, for the whole sector, I believe Immutep has a chance to deliver and show a difference in terms of quality, and we are very much looking forward to that.
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-346
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.5¢ |
Change
0.005(1.67%) |
Mkt cap ! $443.0M |
Open | High | Low | Value | Volume |
30.5¢ | 31.3¢ | 30.0¢ | $381.6K | 1.247M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 74522 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 173496 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 112270 | 0.305 |
12 | 160248 | 0.300 |
9 | 115616 | 0.295 |
13 | 86801 | 0.290 |
8 | 189898 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 207556 | 14 |
0.315 | 239775 | 10 |
0.320 | 58847 | 7 |
0.325 | 91828 | 8 |
0.330 | 217387 | 6 |
Last trade - 11.52am 09/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |